At eight o'clock on a weekday morning, the telephone lines at a typical GP surgery open and the day's appointments disappear within minutes. Those who secure a slot are, rightly, the ones with symptoms. Somewhere in the same postcode sits a forty-five-year-old whose parents died young of heart disease, who feels well and has no complaint to report. That person has no route into the health service until something goes wrong. The NHS has acknowledged the gap for years and has never had the capacity to close it.

The government now says it intends to. The 10 Year Health Plan commits the service to a shift from sickness to prevention, from hospital to community and from analogue to digital. The ambition is widely shared. Delivery depends on the same workforce and budgets already stretched by waiting lists, urgent care demand and a slow recovery from industrial action. Prevention repays its cost over decades, while operational pressure arrives every winter. Few trust leaders have the headroom to build population-scale risk assessment from scratch.

This is the context in which the £4.6 million seed round raised by Stride deserves attention. The company was launched in May 2024 by Andrew Steele, an Olympic medallist and co-founder of DNAfit, and combines DNA, blood and gut testing with personalised guidance so that members can see their health data and track it over time. Its backers include Arāya Ventures, Morgan Stanley Inclusive & Sustainable Ventures, Better Ventures and Innovate UK, alongside an a16z Scout Fund investor and a group of angels. A blend of public innovation funding and institutional capital is a credible signal for a young company in a field with a mixed reputation.

The more consequential detail sits in the research programme. Innovate UK is supporting two Stride projects. One seeks a multiomic measure of biological age, giving individuals and clinicians a sharper indicator of risk than a birth certificate can offer. The other is an AI-powered health copilot that draws together laboratory results, wearable data and health records to produce personalised insight. Those are the capabilities that the government's health data and life sciences ambitions assume the UK can produce at home. A company building them at seed stage, with public backing, shows strategy turning into product.

For NHS leaders, the practical value lies in what such platforms can feed into the system. A patient who arrives at a consultation holding structured information on lipid levels and inflammation markers is quicker to triage and easier to advise. Integrated care boards looking for population health tools that need no new clinic space will find a provider generating the kind of data that prevention programmes require. Interoperability will decide the outcome. Results that cannot be shared with a GP record, with the patient's consent, have limited clinical worth, so standards and information governance deserve as much attention as the algorithms.

Policymakers face a more delicate task. Consumer testing widens access for those who can pay, and the risk of a two-tier approach to prevention is real. Regulation of clinical validity will need to keep pace, particularly as AI models interpret personal data. Yet a well-governed market can serve the public interest by identifying risk early at no cost to the Exchequer and by building an evidence base that public services could adopt later at scale. Stride's partnerships with Triple Bond at The BoTree Hotel and LongLane, an alcohol-free biohacking destination, take testing into settings where people are already receptive to changing habits. Its plan to launch Stride One outside the UK before the end of 2026 adds an export dimension, with British technology earning revenue abroad.

Steele has said that preventative health can sound boring or worthy, and that making it engaging could change behaviour at scale. The NHS has spent decades learning how hard that is to achieve through leaflets and public campaigns. The state has set the direction, and a young British company is now building part of the road. If the health service can connect to it safely, with clear standards, prevention may reach that forty-five-year-old in the same postcode before the symptoms do.

‍